capital raising, page-7

Dendreon article out tonight tags Prima on the end

Nice to see

"Provenge is an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer developed by US biotech Dendreon. Provenge is made using cells from a patient's own immune system, so it cannot be warehoused like many other drugs and requires specialized manufacturing facilities."

"Provenge is administered to treat prostate cancer in patients during the final stages of the illness. Provenge treatment is a staggering $93,000 which includes 3 infusions at a cost of $31,000 each, valuing each month of life at $23,000. Medicare has agreed to cover some costs through its program. Approximately 2,000 patients will under go treatment this year."

"Quarter one sales for Provenge were $US 28.1 million which was slightly less than the expected $US29 million. Dendreon plan to increase the production of their New Jersey Manufacturing facility to full capacity after receiving Approval by US Food & Drug Administration in March."

"Australian biotech Prima Biomed is also looking to enter the market with their own cvac product."

Click here for source